Asian Tech Press (Dec 13) -- A new Israeli study shows that a booster dose of the COVID-19 vaccine Comirnaty, which was co-developed by Pfizer Inc. and German company BioNTech SE, is effective against the Omicron variant, the Wall Street Journal reported Sunday.

The report said that a three-shot course of the Pfizer-BioNTech COVID-19 vaccine provides important protection against the Omicron variant, but is only 1/4 as effective as protection against Delta.

Pfizer and BioNTech have been working on an Omicron-based vaccine, which they hope to launch by in March 2022.